Transcript PowerPoint Presentation - aktiv

The CAN-BD®*
Process
*Carbon dioxide Assisted Nebulization
with a Bubble Dryer
AKTIV-DRY
6060 Spine Road  Boulder CO 80301
303-350-3060  www.aktiv-dry.com
Supercritical
CO2
(80 to 100 atm)
Drug solution
or suspension
Flow restrictor tube
ID = 75 µm
10 cm
Restrictor tip
Plume
CO2
flashes
upon
rapid
100X
decompression to atmospheric pressure
• Very narrow size distribution range
• Drying takes place in seconds, not hours
• Continuous process
• Environmentally friendly - Uses CO2 and
water for most applications
• Compatible with organics
• No toxic residues or waste to create
disposal problems
• Lower temperatures minimize
decomposition of thermally liable materials
such as certain drugs and proteins
CAN-BD is Aktiv-Dry’s proprietary
process for making fine, dry powders of
pharmaceutical, biotech, and other
compounds. The heart of CAN-BD is high
pressure
nebulization
assisted
by
supercritical fluids, usually CO2, but N2
has also been used.
Nebulization occurs when the supercritical,
or near-critical, fluid mixes with a solution
or suspension of the pharmaceutical
product to form an emulsion that expands
abruptly from 80 bar to atmospheric
pressure through a capillary flow restrictor.
Microbubbles that form during the
expansion burst almost instantaneously at
atmospheric pressure to create a plume of
billions of nano-scale droplets.
When the plume is directed into a drying
chamber, not unlike that used in spray
drying, the liquid solvent evaporates to
leave behind fine particles that may be
collected on filters, bags, or in cyclone
separators.
Particle size distributions may be
engineered by changing process variables.
CAN-BD has been used with aqueous and
organic solvents and with nanosuspensions.
Solutes have included
proteins, peptides, live vaccines and many
other compounds and excipients.
CAN-BD is capable of making particles for virtually any application, including dry
pharmaceutical powders for pulmonary drug delivery